g(m1)-ganglioside and Diabetic-Neuropathies

g(m1)-ganglioside has been researched along with Diabetic-Neuropathies* in 2 studies

Other Studies

2 other study(ies) available for g(m1)-ganglioside and Diabetic-Neuropathies

Article	Year
Anti-ganglioside GM1 antibody and distal symmetric "diabetic polyneuropathy" with dominant motor features. Diabetologia, 1997, Volume: 40, Issue:11 Topics: Autoantigens; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Female; G(M1) Ganglioside; Humans; Male; Middle Aged; Motor Neuron Disease	1997
Inner ester derivatives of gangliosides protect autonomic nerves of alloxan-diabetic rats against Na+, K(+)-ATPase activity defects. Diabetes research and clinical practice, 1991, Volume: 12, Issue:2 Bovine brain gangliosides have been shown to prevent decay in Na+,K(+)-ATPase activity in sciatic and optic nerves of alloxan- and streptozotocin-diabetic rats. In the search for a drug with greater bioavailability and increased incorporation into neural tissue, ganglioside inner ester derivatives (AGF1) were recently developed. We evaluated the effect of AGF1 treatment on Na+,K(+)-ATPase activity in homogenates of vagus nerve from alloxan-diabetic rats (100 mg/kg s.c.). Animals were treated with AGF1: 10 mg/kg 6 days/week i.p., or 30 mg/kg biweekly i.p. Treatment began 10 d post-alloxan and continued for 8 consecutive weeks. Normal age- and sex-matched rats were used as controls. Alloxan intoxication produced a 39% decrease in Na+,K(+)-ATPase activity of the vagus nerve, which was completely restored (96-97% recovery) by both AGF1 regimes. Results suggest that ganglioside inner ester derivatives may be used in the clinical setting for the management of diabetic autonomic neuropathy. Topics: Animals; Blood Glucose; Body Weight; Ca(2+) Mg(2+)-ATPase; Diabetes Mellitus, Experimental; Diabetic Neuropathies; G(M1) Ganglioside; Gangliosides; Glycated Hemoglobin; Male; Molecular Structure; Rats; Rats, Inbred Strains; Reference Values; Sodium-Potassium-Exchanging ATPase; Vagus Nerve	1991

Article

Year

Anti-ganglioside GM1 antibody and distal symmetric "diabetic polyneuropathy" with dominant motor features.

Diabetologia, 1997, Volume: 40, Issue:11

Topics: Autoantigens; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Female; G(M1) Ganglioside; Humans; Male; Middle Aged; Motor Neuron Disease

1997

Inner ester derivatives of gangliosides protect autonomic nerves of alloxan-diabetic rats against Na+, K(+)-ATPase activity defects.

Diabetes research and clinical practice, 1991, Volume: 12, Issue:2

Bovine brain gangliosides have been shown to prevent decay in Na+,K(+)-ATPase activity in sciatic and optic nerves of alloxan- and streptozotocin-diabetic rats. In the search for a drug with greater bioavailability and increased incorporation into neural tissue, ganglioside inner ester derivatives (AGF1) were recently developed. We evaluated the effect of AGF1 treatment on Na+,K(+)-ATPase activity in homogenates of vagus nerve from alloxan-diabetic rats (100 mg/kg s.c.). Animals were treated with AGF1: 10 mg/kg 6 days/week i.p., or 30 mg/kg biweekly i.p. Treatment began 10 d post-alloxan and continued for 8 consecutive weeks. Normal age- and sex-matched rats were used as controls. Alloxan intoxication produced a 39% decrease in Na+,K(+)-ATPase activity of the vagus nerve, which was completely restored (96-97% recovery) by both AGF1 regimes. Results suggest that ganglioside inner ester derivatives may be used in the clinical setting for the management of diabetic autonomic neuropathy.

Topics: Animals; Blood Glucose; Body Weight; Ca(2+) Mg(2+)-ATPase; Diabetes Mellitus, Experimental; Diabetic Neuropathies; G(M1) Ganglioside; Gangliosides; Glycated Hemoglobin; Male; Molecular Structure; Rats; Rats, Inbred Strains; Reference Values; Sodium-Potassium-Exchanging ATPase; Vagus Nerve

1991